Patents Assigned to UNIVERSITE DE PARIS XI PARIS SUD
  • Strigolactone analogues and the use thereof for the treatment of plants
    Patent number: 9532569
    Abstract: A compound of general formula (I): in which X represents O, S, NH or an N-alkyl radical, R1 and R2, identical or different, each represent H or a C1-C10 hydrocarbon radical, R1 and R2 not both representing H, R3 represents a C1-C10 hydrocarbon radical, and R represents a phenyl radical monosubstituted or disubstituted by a substituent Y and, if applicable, a substituent Z, chosen from Cl, Br, I and CF3, or R represents a C?R4(R5) radical in which R4 represents an hydrocarbon radical and R5 represents a linear or branched, saturated or unsaturated, hydrocarbon radical, optionally substituted, a COR6 group or a CO2R6 group, where R6 represents a hydrogen atom or a linear or branched, saturated or unsaturated, hydrocarbon radical. This compound can be used for the treatment of higher plants for controlling their growth and architecture.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: January 3, 2017
    Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE PARIS XI PARIS SUD
    Inventors: Francois-Didier Boyer, Catherine Rameau, Jean-Paul Pillot, Vincent Servajean, Alexandre De Saint Germain, Jean-Marie Beau, Jean-Bernard Pouvreau, Guillaume Clave
  • Methods for cancer management targeting Co-029
    Patent number: 9487586
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: November 8, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE DE PARIS XI PARIS SUD
    Inventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
  • METHODS FOR CANCER MANAGEMENT TARGETING CO-029
    Publication number: 20150291691
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Application
    Filed: April 21, 2015
    Publication date: October 15, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE DE PARIS XI PARIS SUD
    Inventors: Eric RUBINSTEIN, Céline GRECO, François LE NAOUR, Claude BOUCHEIX